Understanding Tecvayli

Tecvayli™ (teclistmab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma. Tecvayli is indicated for patients with relapsed or refractory myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli is an immunotherapy, a treatment that enhances the patient’s own immune system to attack their myeloma cells.